Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

By A. Ramsay, A. Johnson, Abigail M. Lee, Güllü Gorgün, Rifca Le dieu, W. Blum, J. Byrd, J. Gribben. Journal of Clinical Investigation, 2008

630 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (2015, background): “Many mechanisms that lead to local immunologic inhibition have been identified in patientswithCLL including the inability of T cells to synapse appropriately with leukemia cells, the production of immunosuppressive cytokines within the microenvironment, and possible overexpression of immune checkpoi”
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. (2013, background): “In CLL, an increasingly defective immune synapse enables malignant B cells to evade immune detection by inducing T-cell anergy as well as improper Th2 polarization.(24,25) In addition to being incapable of responding to environmental pathogens, these improperly polarized T cells contribute both cyto”
From pathogenesis to treatment of chronic lymphocytic leukaemia (2010, background): “CLL cells also induce phenotypical changes in T cells, the most prominent of which is a defective and reduced formation of the immunological synapse”